# A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)

> **NCT00854308** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 137 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib HCl
- **DRUG:** MetMAb
- **DRUG:** placebo (0.9 % saline)

## Key facts

- **NCT ID:** NCT00854308
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-11
- **Final completion:** 2012-01
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2017-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00854308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00854308, "A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00854308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*